Corpus Intelligence IC Memo — INTERFAITH MEDICAL CENTER 2026-04-26 07:38 UTC
IC Memo — INTERFAITH MEDICAL CENTER
Investment Committee Memorandum | NY | 153 beds | Grade C | EBITDA uplift $10.0M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

INTERFAITH MEDICAL CENTER

CCN 330397 | KINGS, NY | 153 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

INTERFAITH MEDICAL CENTER is a 153-bed under-performing / distressed in KINGS, NY with $135.8M in net patient revenue and a -88.0% operating margin. The hospital serves a payer mix of 18.1% Medicare, 16.5% Medicaid, and 65.5% commercial.

Thesis: Undervalued. Our ML models identify $10.0M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -88.0% to -80.6% (+736bps).

Net Revenue HCRIS$135.8M
Current EBITDA COMPUTED$-119.5M
Operating Margin COMPUTED-88.0%
Occupancy HCRIS66.0%
Revenue / Bed COMPUTED$888K
Net-to-Gross HCRIS28.9%
Distress Probability ML47.6%

2. Market Context & Competitive Position

196
NY Hospitals
-17.5%
State Median Margin
98
Comparable Hospitals

NY has 196 Medicare-certified hospitals with a median operating margin of -17.5%. The target's margin of -88.0% places it below the state median. Among 98 size-comparable peers (76-306 beds), the median margin is -16.4%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (76-306), prioritizing same-state peers. 98 hospitals in the comp set.

HospitalStateBedsRevenueMargin
INTERFAITH MEDICAL CENTER (Target)NY153$135.8M-88.0%
HOSPITAL FOR SPECIAL SURGERYNY200$1.12B-29.3%
WHITE PLAINS HOSPITALNY292$884.7M8.7%
ROSWELL PARK CANCER INSTITUTENY142$772.3M-40.1%
LINCOLN MEDICAL&MENTAL HEALTH NY287$693.5M-22.9%
QUEENS HOSPITAL CENTERNY200$637.2M4.9%
JAMAICA HOSPITAL MEDICAL CENTENY280$610.4M-18.6%
NYC HEALTH + HOSPITAL / SOUTH NY252$588.5M-16.5%
THE UNITY HOSPITAL OF ROCHESTENY283$571.5M-17.8%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $10.0M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$2.9M+210bp18mo
Cost to Collect4.5%2.5%$2.7M+200bp12mo
Denial Rate Reduction12.0%6.5%$2.7M+198bp12mo
A/R Days Reduction5200.0%3800.0%$1.7M+122bp9mo
Clean Claim Rate88.0%96.0%$87K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$2.9M
Cost to Collect
$2.7M
Denial Rate Reduction
$2.7M
A/R Days Reduction
$1.7M
Clean Claim Rate
$87K
Total EBITDA Uplift$10.0M
Current EBITDA$-119.5M
+ RCM Uplift+$10.0M
Pro Forma EBITDA$-109.5M
Current Margin-88.0%
Pro Forma Margin-80.6%
WC Released (1x)$5.2M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-183.8M$-688.2M0.00x-100.0%
Base (11x exit)10.0x11.0x$-183.8M$-816.7M0.00x-100.0%
Bull Case9.0x11.0x$-165.4M$-843.4M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-165.4M$-968.9M0.00x-100.0%
Bear Case11.0x10.0x$-202.2M$-678.5M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-202.2M$-812.0M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 98 hospitals with 76-306 beds
  • Same-state prioritization (n=99)
  • Comp margins: P25=-25.7% / P50=-16.4% / P75=-9.1%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.